奥沙利铂过敏的临床特征分析  

Clinical characteristics of oxaliplatin-induced hypersensitivity reactions

作　　者：杜春霞[1] 洪若熙[1] 陈喆[2] 王金万[1] 周爱萍[1] 

机构地区：[1]中国医学科学院肿瘤医院内科,北京100021 [2]中国医学科学院肿瘤医院药剂科,北京100021

出　　处：《中国肿瘤临床与康复》2014年第2期194-197,共4页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探索奥沙利铂过敏的发生率和临床特征。方法收集2008年3月至2012年12月期间曾接受至少1次奥沙利铂治疗的194例患者的临床资料，分析奥沙利铂过敏的临床特征。结果194例患者中，21例（10．8％）发生过敏反应，其中3～4度过敏发生率为4．6％。过敏最常发生于第7—8个周期，发生率为7．3％。延迟性发热是最常见的过敏症状；以呼吸和循环系统症状为主要过敏表现者，症状发生最快、程度最严重。结论中国患者奥沙利铂过敏发生率与两方人群或其他亚洲人群类似。第7～8个周期过敏发生率最高，严重过敏多发生在输注开始前10min，提醒临床医生在此期间密切关注。Objective To explore the incidence and clinical characteristics of oxaliplatin （L- OHP） -induced hypersensitivity reactions （HRs） in Chinese patients. Methods Clinical information of all patients treated with L-OHP at least once between March 2008 and December 2012 was collected. Detail da- ta from patients who experienced HRs were analyzed. Results Among 194 patients receiving L-OHP-based chemotherapy ,21 （ 10. 8% ） experienced HRs. Grade 3/4 events occurred in 4. 6%. HRs occurred most fre- quently in cycle 7-sth （ incidence 7.3% ）. The most common symptom of HRs was delayed pyrexia. The fas- test and severest HRs were observed in those manifesting mainly with respiratory or cardiac symp- toms. Conclusions The reaearch data shows the incidence of HRs to L-OHP in Chinese patients is similar to that in western population and other eastern Asian populations. Precautions are recommended for firstl0 minutes since onset of infusion and cycle 7-Sth, given the most serious events and the peak of incidence ob- served during this period.

关 键 词：奥沙利铂 过敏反应 发热 

分 类 号：R730.5[医药卫生—肿瘤]